The development of effective treatment for ischemic stroke, which is a common cause of
morbidity and mortality worldwide, remains an unmet goal because the current first-line
treatment management interventional therapy has a strict time window and serious
complications. In recent years, a growing body of evidence has shown that the elevation of
intracellular and extracellular cyclic adenosine monophosphate (cAMP) alleviates brain
damage after ischemic stroke by attenuating neuroinflammation in the central nervous …